Share this article
DEFIANCE, Ohio, May 12, 2021 /PRNewswire/
SB Financial Group, Inc. (NASDAQ: SBFG) ( SB Financial or the Company ), a diversified financial services company providing full-service community banking, mortgage banking, wealth management, private client and title insurance services, today announced it has been named to the 2021 Keefe, Bruyette & Woods, Inc. Bank Honor Roll of superior performers.
KBW, a full–service, boutique investment bank and broker–dealer that specializes in the financial services sector, found that 16 banking institutions, just 4% of the nearly 400 banks screened, qualified for inclusion on its Bank Honor Roll in 2021. Of note, Honor Roll winners are publicly traded banking institutions with more than $500 million in total assets that consistently reported increases in earnings per share over the last decade.
Lake City Bank Named to KBW Bank Honor Roll of High Performing Banks for the 10th Consecutive Year streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Confirm
WARSAW, Ind., May 04, 2021 (GLOBE NEWSWIRE) Lake City Bank, the single bank subsidiary of Lakeland Financial Corporation (Nasdaq Global Select/LKFN), announced today that the bank was included in the 2021 KBW Bank Honor Roll published by Keefe Bruyette & Woods (KBW), the 10
th consecutive year that the bank has earned a place in the listing.
Lake City Bank is one of 16 banking institutions, just 4% of all banks screened, that met KBW’s criteria for inclusion in the 2021 Bank Honor Roll; 13 banks are returning members to the list. KBW Bank Honor Roll members have better-than industry performance ratios and growth rates when compared to the publicly traded bank universe with total assets greater than $500 million, which includes 365 companies listed on the and Nasdaq exchanges.
+44 (0)20 7933 8780 or [email protected]
Paul McManus, Alice Woodings ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop off the shelf stem cell treatments, without the need for immunosuppressive drugs. The Company s lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.